Compare

Compare stocks side by side

Pick up to 3 companies to see where each one is stronger or weaker.

BMYLLY

Bristol-Myers Squibb Company

BMY · $61.52

60Good

Eli Lilly and Company

LLY · $1273.46

70Good

Area by area

Overall Quant Score

How does it look overall? (out of 100)

BMY

60/100

LLY

70/100

Quality

Is it a profitable, well-run business?

BMY

8.1/10

LLY

9.4/10

Growth

Is the company growing?

BMY

4.5/10

LLY

10.0/10

Valuation

Is the price reasonable? (higher = cheaper)

BMY

9.8/10

LLY

3.4/10

Risk

How risky are the shares? (higher = lower risk)

BMY

7.6/10

LLY

7.4/10

Momentum

Is the share price trending up?

BMY

8.0/10

LLY

9.5/10

Financial strength

Is the balance sheet healthy?

BMY

3.7/10

LLY

7.1/10

The balanced view

Model-generated

Bristol-Myers Squibb Company

This company scores above average, with a reasonable valuation and strong profitability, although analysts are cautious.

Leads on: valuation, risk

Best feature: reasonable valuation (PEG: 0.16)

Watch out: analysts are cautious (Analyst buy share: 45%)

Eli Lilly and Company

This company scores above average, with solid growth and a positive price trend, although its current valuation deserves attention.

Leads on: quality, growth, momentum, financial strength

Best feature: solid growth (Revenue growth (FY): 44.7%)

Watch out: valuation may be demanding (DCF upside: -43.2%)

Different strengths suit different goals — a higher score in one area doesn’t make a stock the better choice for everyone.